Apocrine breast cancer is an uncommon type of invasive breast cancer, named not for where it starts but for how its cells look under the microscope: they resemble apocrine cells, the kind found in sweat glands. It is usually grouped with the invasive cancers, and its test results often look different from the most common types — many apocrine cancers test negative for the estrogen and progesterone receptors, for example. What the diagnosis means for any one person depends on their full pathology report, so this guide explains the features in general terms and leaves the specifics to your own care team.
Key Takeaways
- “Apocrine” describes how the cancer cells look under the microscope — large cells resembling sweat-gland cells — rather than a different place of origin.
- It is an uncommon type of invasive breast cancer; current figures are published by the American Cancer Society (cancer.org) and the National Cancer Institute (cancer.gov).
- Many apocrine cancers are hormone receptor negative and HER2 negative on testing, a pattern often called triple negative, though HER2-positive apocrine cancers also occur.
- Diagnosis rests on the pathology examination of biopsy tissue; the cell appearance is what earns the name.
- Treatment is planned the way it is for other invasive breast cancers — around the stage, the receptor and HER2 results, and your overall health — not around the word “apocrine” alone.
- Individual cases differ, and your own team’s reading of your report governs your plan.
What “Apocrine” Actually Means
Pathologists name many breast cancers by features they can see. Under the microscope, apocrine cancer cells are large, with abundant grainy-looking cell material and prominent centres (nuclei). They resemble the apocrine sweat-gland cells found in places like the armpit — hence the name. It does not mean the cancer started in a sweat gland, and it does not mean you have a sweat-gland condition. It is a description of appearance, recorded because appearance is one of the clues pathologists use to classify a cancer.
Apocrine features can appear in more than one setting. Sometimes an invasive cancer is made up largely of apocrine-type cells and is reported as apocrine carcinoma. Sometimes apocrine change is noted in non-invasive findings too, where it is usually a benign or in-situ change rather than an invasive cancer. Our pillar guide, Types of Breast Cancer Compared, shows where named types like this one sit within the wider classification, and our guide to understanding your pathology report walks through the terms a report uses.
How It Is Found and Diagnosed
There is nothing about how apocrine cancer is found that sets it apart. It may be picked up on a screening mammogram, or it may present as a lump or another change that is then examined. As with other breast cancers, the diagnosis itself comes from tissue: a biopsy sample is examined by a pathologist, who confirms that the cancer is invasive (able to grow into surrounding tissue) and studies the cells’ appearance, grade, and test results.
Because the apocrine label depends on what the cells look like, it is the pathology examination — not the mammogram and not how the lump feels — that decides whether the word appears in your report. If your report mentions apocrine features alongside another type name, that usually means the cancer shows a mixture of appearances, and the report’s main classification is the one your team will work from.
The Receptor Pattern: Often Different
Three test results shape most breast cancer planning: the estrogen receptor (ER), the progesterone receptor (PR), and HER2. In apocrine cancers, the pattern is often distinctive. Many are ER negative and PR negative — the cancer is not being driven by those hormones, so hormone therapy is not usually part of the picture for them. HER2 results vary: some apocrine cancers are HER2 positive and some are HER2 negative. When all three tests are negative, the cancer falls into the group called triple negative, which our explainer on triple negative breast cancer describes in full.
One further test is sometimes mentioned with apocrine cancers: the androgen receptor, which responds to hormones such as testosterone. Apocrine cancers quite often show this receptor. At present it is mainly a classifying feature — your team can tell you whether it was tested in your case and whether it changes anything about your plan. Our article on ER, PR, and HER2 testing explains what each of these results means and how they are reported.
How It Compares With Other Types
| Feature | Apocrine breast cancer | Most common invasive cancers |
|---|---|---|
| What the name describes | The cells’ appearance under the microscope — resembling sweat-gland cells | Usually the structure the cancer grows in, such as ducts or lobules |
| How common | Uncommon — one of the rarer named types | The majority of diagnoses |
| Typical hormone receptor results | Often ER and PR negative; HER2 varies | Often ER and/or PR positive; HER2 varies |
| What mainly drives the plan | Stage, grade, receptor and HER2 results, overall health | Stage, grade, receptor and HER2 results, overall health |
Apocrine cancer belongs to a loose family of uncommon named types, each defined by its own microscopic pattern. Our explainers on metaplastic breast cancer, secretory breast carcinoma, and adenoid cystic carcinoma of the breast cover three others. The practical lesson of the table is the last row: whatever the type name, the same core information drives planning.
How Treatment Is Generally Planned
There is no separate “apocrine treatment.” Plans are built the way they are for other invasive breast cancers: surgery to remove the cancer is usually the foundation when the cancer has not spread distantly; radiation therapy may be part of the plan depending on the surgery and the cancer’s extent; and drug treatments are chosen from the receptor and HER2 results — HER2-targeted therapy when HER2 is positive, chemotherapy in many receptor-negative cases, and hormone therapy only when the receptors suggest it could help.
Because apocrine cancers are uncommon, you may find less written about them than about the common types, and what you do find may seem contradictory — older descriptions were written before today’s receptor testing sorted cancers more precisely. It is reasonable to ask your team how much the apocrine features themselves, as opposed to the stage and test results, are influencing their recommendations. In most plans, the honest answer is that stage and biology do the heavy lifting. General information about how breast cancers are classified and treated is published by the National Cancer Institute at cancer.gov and the American Cancer Society at cancer.org.
Questions to Ask Your Doctor
- Does my report describe a pure apocrine cancer, or apocrine features within another type?
- What were my ER, PR, and HER2 results, and was the androgen receptor tested?
- What stage and grade is the cancer, and how do those shape my plan?
- Which treatments are being considered for me, and what is each one for?
- Do the apocrine features themselves change any part of the plan, or is it driven by stage and test results?
- Is there anything about follow-up that differs in my case?
Frequently Asked Questions
Is apocrine breast cancer a separate disease from other breast cancers?
It is a type of invasive breast cancer, distinguished by how its cells look under the microscope. It is diagnosed, staged, and planned for within the same framework as other invasive breast cancers, with treatment choices driven mainly by stage and the receptor and HER2 results.
Does “apocrine” mean the cancer came from a sweat gland?
No. The name records a resemblance: the cancer cells look like apocrine sweat-gland cells. The cancer is a breast cancer, arising in breast tissue, and it is treated as one.
Is apocrine breast cancer more serious than other types?
There is no simple ranking this article can give you, and older descriptions are hard to compare because testing has changed how these cancers are classified. What shapes an individual situation is the stage, the grade, and the test results — your team can explain how those factors combine in your own report.
If my apocrine cancer is triple negative, does that settle my treatment?
Triple negative results do shape the drug treatments considered — chemotherapy is commonly part of the discussion, and hormone therapy is not — but stage, overall health, and your own preferences also matter. It is a starting point for the plan, not the whole plan.
Should I ask for a second opinion because this type is uncommon?
A second opinion is a reasonable step for anyone who wants one, and uncommon diagnoses are a common reason people seek one. Your team will be used to the request and can help with sending your pathology material.
Related Articles
- Types of Breast Cancer Compared: A Complete Guide
- Metaplastic Breast Cancer Explained
- Secretory Breast Carcinoma Explained
- Adenoid Cystic Carcinoma of the Breast Explained
- Triple Negative Breast Cancer, Explained
- Understanding Your Breast Cancer Pathology Report
This article is for general educational purposes only and is not medical, legal, or financial advice. It does not replace professional care. Talk to your doctor or care team about your own situation. If you think you may have a medical emergency, call 911.